UBS Group’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-156,254
| Closed | -$3.04M | – | 11060 |
|
|
2024
Q4 | $3.04M | Buy |
156,254
+78,270
| +100% | +$1.45M | ﹤0.01% | 4313 |
|
|
2024
Q3 | $1.22M | Buy |
+77,984
| New | +$693K | ﹤0.01% | 4475 |
|
|
2024
Q2 | – | Sell |
-73,646
| Closed | -$1.14M | – | 10330 |
|
|
2024
Q1 | $1.14M | Buy |
73,646
+1
| +0% | +$15 | ﹤0.01% | 4498 |
|
|
2023
Q4 | $1.02M | Hold |
73,645
| – | – | ﹤0.01% | 4480 |
|
|
2023
Q3 | $842K | Sell |
73,645
-82,344
| -53% | -$1.53M | ﹤0.01% | 4237 |
|
|
2023
Q2 | $3.88M | Sell |
155,989
-603
| -0.4% | -$17.7K | ﹤0.01% | 2831 |
|
|
2023
Q1 | $5.68M | Sell |
156,592
-90
| -0.1% | -$5.51K | ﹤0.01% | 2396 |
|
|
2022
Q4 | $9.45M | Buy |
156,682
+834
| +0.5% | +$55.9K | ﹤0.01% | 1971 |
|
|
2022
Q3 | $11.7M | Buy |
155,848
+4,782
| +3% | +$500K | 0.01% | 1662 |
|
|
2022
Q2 | $17.3M | Sell |
151,066
-1,125
| -0.7% | -$132K | 0.01% | 1409 |
|
|
2022
Q1 | $28.8M | Buy |
152,191
+148,494
| +4,017% | +$34.4M | 0.01% | 1178 |
|
|
2021
Q4 | $1.28M | Buy |
3,697
+3,002
| +432% | +$1.16M | ﹤0.01% | 4169 |
|
|
2021
Q3 | $233K | Buy |
695
+692
| +23,067% | +$355K | ﹤0.01% | 5205 |
|
|
2021
Q2 | $3K | Buy |
+3
| New | +$2.33K | ﹤0.01% | 8858 |
|
UBS Group's OMIC Position: Q1 2025 in Review
UBS Group sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2025, closing a stake of 156,254 shares — an estimated $3.04M sold.
UBS Group first reported a position in OMIC in Q2 2021 and held it in 14 quarters. The position peaked at $28.8M in Q1 2022. 0 funds tracked by Wall St. Rank hold OMIC as of Q1 2025.
- UBS Group reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 156,254 Singular Genomics Systems, Inc. Common Stock shares in Q1 2025, an estimated $3.04M.
- UBS Group first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 14 quarters.
- UBS Group's Singular Genomics Systems, Inc. Common Stock position peaked at $28.8M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.